Last reviewed · How we verify

Foscavir — Competitive Intelligence Brief

Foscavir (FOSCARNET) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pyrophosphate Analog DNA Polymerase Inhibitor. Area: Immunology.

marketed Pyrophosphate Analog DNA Polymerase Inhibitor Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Foscavir (FOSCARNET) — Clinigen Hlthcare. Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Foscavir TARGET FOSCARNET Clinigen Hlthcare marketed Pyrophosphate Analog DNA Polymerase Inhibitor 1991-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pyrophosphate Analog DNA Polymerase Inhibitor class)

  1. Clinigen Hlthcare · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Foscavir — Competitive Intelligence Brief. https://druglandscape.com/ci/foscarnet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: